Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Cubist Pharmaceuticals

Related CBST
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Benzinga's Weekend M&A Chatter

In a report published on Wednesday, Cantor Fitzgerald analyst Irina Rivkind raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $50.00 to $65.00 and maintained a Hold rating on the stock.

In the report, Cantor Fitzgerald cited recent announcements by Cubist to acquire Optimer Pharmaceuticals and Trius Therapeutics, stating, "Management estimates that these two new assets combined could add $0.6-1.0B in peak revenues, with minimal incremental SG&A investment."

Cubist Pharmaceuticals closed Tuesday at $57.00.

Latest Ratings for CBST

DateFirmActionFromTo
Jul 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform
Jun 2014JefferiesMaintainsBuy
Jun 2014Gabelli & Co.Initiates Coverage onBuy

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Price Target Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters